Phase 3 Study of KP-100IT in Subjects With Acute Spinal Cord Injury

Inclusion Criteria: * At the time of consent (whether oral or written consent), the patient's age is over 18 years old and under 89 years old * Patients who have suffered a cervical spinal cord injury within the past 78 hours whose AIS classification was A at 66 - 78 hours after injury-Written informed consent has been obtained Exclusion Criteria: * The injury site is C1-C2 or C2-C3 * The patient cannot start rehabilitation necessary for recovery of function at an early stage, for example because tracheal intubation, tracheotomy, or mechanical ventilatory support is necessary * It is predicted that it will not be possible to administer the first dose of the study drug within 78 hours after the cervical spinal cord injury * A history of SCI (Spinal cord injury), or abnormal findings in the spinal cavity or marked breakdown of the meninges other than SCI * Efficacy and safety cannot be evaluated properly due to such as concurrent multiple external trauma or concurrent organ injury * High dose steroid therapy administered for spinal cord injury * Disease such as serious liver disorder, renal disease, heart disease, blood dyscrasia, metabolic disease, or infections requiring systemic therapy * History of malignant tumor * Participation in a clinical study or research of pharmaceuticals or medical devices within 1 month before registration * Drug allergies to drugs that will be (or may be) used * Administration of the study drug to the site of spinal cord injury is inappropriate for a reason such as intrathecal infection or intrathecal mass * Problems with the subject's ability to give informed consent in person * The subject is breastfeeding or possibly pregnant * The subject cannot be expected to survive more than 180 days after the start of administration of the study drug, in the judgement of the investigator * It is inappropriate for the subject to be included in the study, in the judgement of the investigator